Secarna Pharmaceuticals and Vect-Horus Announce Research Collaboration to Advance Systemic Delivery of RNA-Targeted Therapeutics for CNS Disorders

We are proud and excited to announce a new strategic research collaboration with Secarna Pharmaceuticals!

The partnership will focus on developing RNA-targeted therapeutics capable of crossing the blood-brain barrier (BBB) to address diseases of the central nervous system (CNS), combining our delivery technology platform, VECTrans®, with Secarna’s proprietary OligoCreator® oligonucleotide discovery platform.

The combination of these two technologies will expand Secarna’s targeted delivery portfolio, offering a novel approach that could potentially transform the treatment of neurodegenerative diseases.

“This research collaboration represents a unique opportunity to overcome the long-standing delivery challenges through the blood-brain barrier and bring forward innovative treatment options for patients who today have limited and ineffective treatment option,” says Alexandre Tokay, co-founder and CEO of Vect-Horus.

Click here for the full press release : https://www.globenewswire.com/fr/news-release/2025/07/10/3113000/0/fr/Secarna-Pharmaceuticals-et-Vect-Horus-annoncent-un-programme-de-recherche-pour-le-transport-cibl%C3%A9-des-th%C3%A9rapies-visant-l-ARN-pour-traiter-les-maladies-du-syst%C3%A8me-nerveux-central.html